News

Access and download our newsletters from the Newsletter Archive

 
 

As well as keeping you up to date with the latest developments within the life sciences sector, Bionow members can also post updates to the Bionow News page to promote themselves to over 300 Bionow member organisations and the UK Life Sciences sector.

Whether currently a member or not, keep up to date with all the latest news and events by registering to receive the Bionow newsletter.

Contracts worth over £500,000 with the potential for downstream milestone and royalty/ licensing payments

Aptamer Group announces a selection of new contract wins where Optimer technology is being explored by partners to offer new strategies for therapeutics and potentially offer improved assay ...

Aptamer Group’s CEO, Dr Arron Tolley, has been awarded a Visiting Professorship in Biological and Translational Sciences from the Faculty of Health and Medical Sciences, University of Surr...

Aptamer Group celebrated its recent Admission to AIM on Friday evening, with an exclusive party at the Sora Sky bar in the Malmaison hotel, York.

Aptamer Group announces admission to trading on AIM

Aptamer Group and ValitaCell have entered a long-term collaboration with the agreement of commercial terms regarding the development of a next-generation biologic screening platform. The exi...

Aptamer Group Ltd, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has entered into a large-scale Optimer development and...

Aptamer Group, Ltd. the developer of Optimer® binders to enable innovation in the life science industry, and BizCom Japan, Inc., a Japan-based trading and consultancy company, today announc...

Aptamer Group Ltd, the developer of custom affinity tools to enable the life science industry through its proprietary Optimer platform, and Bio-Works Technologies AB, the developer and manuf...

Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today annou...

Aptamer Group Limited, the developer of Optimer™ Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, today announces that they have en...

Aptamer Group and Mologic extend collaboration to CE mark Aptamer Group's SARS-CoV-2 rapid antigen test

Sign up to our Newsletter

Subscribe

* indicates required

Our Valued Sponsors & Partners